279 related articles for article (PubMed ID: 10731113)
21. Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Brodie AH; Mouridsen HT
Am J Clin Oncol; 2003 Aug; 26(4):S17-26. PubMed ID: 12902873
[TBL] [Abstract][Full Text] [Related]
22. Aromatase inhibitors in advanced breast cancer.
Mouridsen HT
Semin Oncol; 2004 Dec; 31(6 Suppl 12):3-8. PubMed ID: 15719595
[TBL] [Abstract][Full Text] [Related]
23. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
Buzdar AU; Vergote I; Sainsbury R
Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.
Ellis MJ; Rosen E; Dressman H; Marks J
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):301-7. PubMed ID: 14623525
[TBL] [Abstract][Full Text] [Related]
25. Letrozole: a review of its use in postmenopausal women with breast cancer.
Simpson D; Curran MP; Perry CM
Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
[TBL] [Abstract][Full Text] [Related]
27. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Carlini P; Frassoldati A; De Marco S; Casali A; Ruggeri EM; Nardi M; Papaldo P; Fabi A; Paoloni F; Cognetti F
Ann Oncol; 2001 Nov; 12(11):1539-43. PubMed ID: 11822752
[TBL] [Abstract][Full Text] [Related]
28. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
29. Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Kemp A; Preen DB; Saunders C; Boyle F; Bulsara M; Holman CD; Malacova E; Roughead EE
PLoS One; 2014; 9(1):e84835. PubMed ID: 24392158
[TBL] [Abstract][Full Text] [Related]
30. A summary of second-line randomized studies of aromatase inhibitors.
Buzdar AU
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):109-14. PubMed ID: 11850214
[TBL] [Abstract][Full Text] [Related]
31. Aromatase inhibitors for breast cancer in postmenopausal women.
Campos SM
Oncologist; 2004; 9(2):126-36. PubMed ID: 15047917
[TBL] [Abstract][Full Text] [Related]
32. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
34. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J
Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542
[TBL] [Abstract][Full Text] [Related]
35. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
36. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
37. Local endocrine effects of aromatase inhibitors within the breast.
Miller WR; Dixon JM
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):93-102. PubMed ID: 11850212
[TBL] [Abstract][Full Text] [Related]
38. Aromatase inhibitors: a dose-response effect?
Smith IE
Endocr Relat Cancer; 1999 Jun; 6(2):245-9. PubMed ID: 10731116
[No Abstract] [Full Text] [Related]
39. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
Eiermann W; Paepke S; Appfelstaedt J; Llombart-Cussac A; Eremin J; Vinholes J; Mauriac L; Ellis M; Lassus M; Chaudri-Ross HA; Dugan M; Borgs M;
Ann Oncol; 2001 Nov; 12(11):1527-32. PubMed ID: 11822750
[TBL] [Abstract][Full Text] [Related]
40. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Murray R
Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]